Skip to Main Content

Author Details

Yan Zeng
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College
2003
44
28
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36694099Bioinformatics Identification of Therapeutic Gene Targets for Gastric Cancer.Adv Ther2023
37338527Identifying the role of NUDCD1 in human tumors from clinical and molecular mechanisms: a study based on comprehensive bioinformatics and experimental validation.Aging (Albany NY)2023
35158773NSAIDs Overcome <i>PIK3CA</i> Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.Cancers (Basel)2022
35929989STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.Clin Cancer Res2022
36052496Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
36052495Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
34261774Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2021
34591642A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.Science2021
30683736Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer.J Exp Med2019
30928629Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity.Eur J Pharmacol2019
29792310BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.Cancer Res2018
29440171Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2018
27986750Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2017
25982282Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.Oncogene2016
26619122Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.J Clin Invest2016
27267892STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.Cancer Prev Res (Phila)2016
27035818Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.J Clin Invest2016
27004400MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.Oncotarget2016
25810010JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.Neoplasia2015
26181029Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.JAMA Oncol2015
26138066Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.Clin Cancer Res2015
24395800Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.Proc Natl Acad Sci U S A2014
24980815Retracted: Guggulsterone inhibits prostate cancer growth via inactivation of Akt regulated by ATP citrate lyase signaling.Oncotarget2014
23619167Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.Cancer Discov2013
23914993Targeting beta-catenin signaling to induce apoptosis in human breast cancer cells by z-guggulsterone and Gugulipid extract of Ayurvedic medicine plant Commiphora mukul.BMC Complement Altern Med2013
22261283δ-Catenin promotes E-cadherin processing and activates β-catenin-mediated signaling: implications on human prostate cancer progression.Biochim Biophys Acta2012
22549947Epigenetic resensitization to platinum in ovarian cancer.Cancer Res2012
21115635Reactive oxygen species-dependent apoptosis by gugulipid extract of Ayurvedic medicine plant Commiphora mukul in human prostate cancer cells is regulated by c-Jun N-terminal kinase.Mol Pharmacol2011
18978817Increased nucleotide polymorphic changes in the 5'-untranslated region of delta-catenin (CTNND2) gene in prostate cancer.Oncogene2009
19384467Cellular responses to cancer chemopreventive agent D,L-sulforaphane in human prostate cancer cells are initiated by mitochondrial reactive oxygen species.Pharm Res2009
19459175Diallyl trisulfide-induced apoptosis in human cancer cells is linked to checkpoint kinase 1-mediated mitotic arrest.Mol Carcinog2009
19223537Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells.Cancer Res2009
19284555delta-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles.Mol Cancer2009
18800351Diallyl trisulfide selectively causes Bax- and Bak-mediated apoptosis in human lung cancer cells.Environ Mol Mutagen2009
19003581Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells.Nutr Cancer2008
17513609Mitochondria-mediated apoptosis by diallyl trisulfide in human prostate cancer cells is associated with generation of reactive oxygen species and regulated by Bax/Bak.Mol Cancer Ther2007
17671214Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase.Cancer Res2007
16965246Diallyl trisulfide inhibits angiogenic features of human umbilical vein endothelial cells by causing Akt inactivation and down-regulation of VEGF and VEGF-R2.Nutr Cancer2006
17121905Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction.Clin Cancer Res2006
16774948Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential.Carcinogenesis2006
15764812Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species.J Biol Chem2005
16275996Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak.Mol Cancer Ther2005
15814648Caspase-dependent apoptosis induction by phenethyl isothiocyanate, a cruciferous vegetable-derived cancer chemopreventive agent, is mediated by Bak and Bax.Clin Cancer Res2005
12771033Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis.Carcinogenesis2003
  • 1 - 44 of 44

Recommended Authors

Guo Chen
China Pharmaceutical University
Career Start Year 2009
Number of shared co-authors 4
Rahul Kumar
Roswell Park Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 2
Juan L Callejas-Valera
Cancer Biology Research Center
Career Start Year 2008
Number of shared co-authors 3
Young K Song
National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 2
Hui Xue
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Career Start Year 2005
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Bin Yan
The University of Hong Kong
Career Start Year 2003
Number of shared co-authors 0
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 0
Chih-Cheng Yang
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2001
Number of shared co-authors 3
Fan Yang
West China Second Hospital, Sichuan University
Career Start Year 2000
Number of shared co-authors 0
Hye Jin You
Research Institute, National Cancer Center
Career Start Year 2000
Number of shared co-authors 0
Aamer M Qazi
The University of Lahore
Career Start Year 1999
Number of shared co-authors 0
Eddy S Yang
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Krishna P Bhat
Department of Neurosurgery at the University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 0
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 2
Nhu-An Pham
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1998
Number of shared co-authors 0
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 2
Erxi Wu
Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin
Career Start Year 1997
Number of shared co-authors 1
Mitchell J Frederick
Baylor College of Medicine
Career Start Year 1995
Number of shared co-authors 3
Barry R Davies
Oncology R&D
Career Start Year 1992
Number of shared co-authors 1
Qimin Zhan
Peking University Cancer Hospital
Career Start Year 1989
Number of shared co-authors 0
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 5
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 8
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 3
Lori S Hart
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 0
David J McConkey
Johns Hopkins School of Medicine
Career Start Year 1986
Number of shared co-authors 4
Massimo Loda
Weill Medical College of Cornell University
Career Start Year 1984
Number of shared co-authors 6
Carter Van Waes
National Institute of Deafness and Other Communication Disorders
Career Start Year 1984
Number of shared co-authors 6
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 0

Collaborators

Jennifer R Grandis
University of California san francisco
Co-authored papers 20
Hua Li
University of California san francisco
Co-authored papers 14
Daniel E Johnson
University of California San Francisco
Co-authored papers 12
Neil E Bhola
Zai Lab (US) LLC
Co-authored papers 8
Umamaheswar Duvvuri
University of Pittsburgh School of Medicine
Co-authored papers 8
Lin Wang
Co-authored papers 8
Julie E Bauman
George Washington University
Co-authored papers 8
Toni M Brand
University of Wisconsin School of Medicine and Public Health
Co-authored papers 7
Simion I Chiosea
University of Pittsburgh
Co-authored papers 6
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Co-authored papers 5
Stefan Hartmann
University Hospital Wurzburg
Co-authored papers 5
Rachel A O'Keefe
University of California San Francisco
Co-authored papers 5
Max V Ranall
University of California San Francisco
Co-authored papers 5
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 5
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 4
Margaret Soucheray
J. David Gladstone Institutes
Co-authored papers 4
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 4
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 3
Patrick K Ha
University of California San Francisco
Co-authored papers 3
Carolyn Kemp
University of Pittsburgh Medical Center, Eye and Ear Institute
Co-authored papers 3
Michelle A Ozbun
The University of New Mexico School of Medicine
Co-authored papers 3
Ann Marie Egloff
Harvard Medical School, Brigham and Women's Hospital
Co-authored papers 2
Yiling Lu
Co-authored papers 2
Patrick Kwok-Shing Ng
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Mi-Ok Kim
University of California san francisco
Co-authored papers 2
Richard P Lifton
The Rockefeller University
Co-authored papers 2
Roy S Herbst
Yale School of Medicine
Co-authored papers 2
Peter S Hammerman
Novartis Institutes for BioMedical Research
Co-authored papers 2
Zhenghe Wang
Co-authored papers 2
Raja R Seethala
University of Pittsburgh Medical Center-Presbyterian
Co-authored papers 1
Release 1.2